These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1151 related items for PubMed ID: 24852077

  • 21. Optimal time for initiation of antiretroviral therapy in asymptomatic, HIV-infected, treatment-naive adults.
    Siegfried N, Uthman OA, Rutherford GW.
    Cochrane Database Syst Rev; 2010 Mar 17; 2010(3):CD008272. PubMed ID: 20238364
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. First-line antiretroviral therapy with nevirapine versus lopinavir-ritonavir based regimens in a resource-limited setting.
    Clumeck N, Mwamba C, Kabeya K, Matanda S, Vaira D, Necsoi C, Kadiebwe D, Delforge M, Kasamba E, Milolo C, Ilunga J, Kapend L.
    AIDS; 2014 May 15; 28(8):1143-53. PubMed ID: 25028911
    [Abstract] [Full Text] [Related]

  • 24. Stavudine, lamivudine and nevirapine combination therapy for treatment of HIV infection and AIDS in adults.
    Siegfried NL, Van Deventer PJ, Mahomed FA, Rutherford GW.
    Cochrane Database Syst Rev; 2006 Apr 19; 2006(2):CD004535. PubMed ID: 16625606
    [Abstract] [Full Text] [Related]

  • 25. Virologic and immunologic outcomes of HIV-infected Ugandan children randomized to lopinavir/ritonavir or nonnucleoside reverse transcriptase inhibitor therapy.
    Ruel TD, Kakuru A, Ikilezi G, Mwangwa F, Dorsey G, Rosenthal PJ, Charlebois E, Havlir D, Kamya M, Achan J.
    J Acquir Immune Defic Syndr; 2014 Apr 15; 65(5):535-41. PubMed ID: 24326597
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Co-formulated abacavir-lamivudine-zidovudine for initial treatment of HIV infection and AIDS.
    Shey MS, Kongnyuy EJ, Alobwede SM, Wiysonge CS.
    Cochrane Database Syst Rev; 2013 Mar 28; 2013(3):CD005481. PubMed ID: 23543540
    [Abstract] [Full Text] [Related]

  • 28. Therapeutic drug monitoring of antiretrovirals for people with HIV.
    Kredo T, Van der Walt JS, Siegfried N, Cohen K.
    Cochrane Database Syst Rev; 2009 Jul 08; (3):CD007268. PubMed ID: 19588422
    [Abstract] [Full Text] [Related]

  • 29. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Mbuagbaw LC, Irlam JH, Spaulding A, Rutherford GW, Siegfried N.
    Cochrane Database Syst Rev; 2010 Dec 08; (12):CD004246. PubMed ID: 21154355
    [Abstract] [Full Text] [Related]

  • 30. Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial.
    Coovadia A, Abrams EJ, Stehlau R, Meyers T, Martens L, Sherman G, Hunt G, Hu CC, Tsai WY, Morris L, Kuhn L.
    JAMA; 2010 Sep 08; 304(10):1082-90. PubMed ID: 20823434
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Pharmacokinetics and virological efficacy after switch to once-daily lopinavir-ritonavir in treatment-experienced HIV-1-infected children.
    Foissac F, Urien S, Hirt D, Frange P, Chaix ML, Treluyer JM, Blanche S.
    Antimicrob Agents Chemother; 2011 Sep 08; 55(9):4320-5. PubMed ID: 21746952
    [Abstract] [Full Text] [Related]

  • 33. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
    Cvetkovic RS, Goa KL.
    Drugs; 2003 Sep 08; 63(8):769-802. PubMed ID: 12662125
    [Abstract] [Full Text] [Related]

  • 34. Switching to Efavirenz Versus Remaining on Ritonavir-boosted Lopinavir in Human Immunodeficiency Virus-infected Children Exposed to Nevirapine: Long-term Outcomes of a Randomized Trial.
    Murnane PM, Strehlau R, Shiau S, Patel F, Mbete N, Hunt G, Abrams EJ, Coovadia A, Kuhn L.
    Clin Infect Dis; 2017 Aug 01; 65(3):477-485. PubMed ID: 28419200
    [Abstract] [Full Text] [Related]

  • 35. Antiretroviral regimens for patients with HIV who fail first-line antiretroviral therapy.
    Humphreys EH, Chang LW, Harris J.
    Cochrane Database Syst Rev; 2010 Jun 16; (6):CD006517. PubMed ID: 20556768
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Lopinavir/ritonavir versus darunavir plus ritonavir for HIV infection: a cost-effectiveness analysis for the United States.
    Simpson KN, Pei PP, Möller J, Baran RW, Dietz B, Woodward W, Migliaccio-Walle K, Caro JJ.
    Pharmacoeconomics; 2013 May 16; 31(5):427-44. PubMed ID: 23620210
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Sustained Viral Suppression in HIV-infected Children on Once-daily Lopinavir/Ritonavir in Clinical Practice.
    Gondrie IPE, Bastiaans DET, Fraaij PLA, Driessen GJA, van der Knaap LC, Visser EG, van Jaarsveld P, de Groot R, Hartwig NG, Burger DM, van Rossum AMC.
    Pediatr Infect Dis J; 2017 Oct 16; 36(10):976-980. PubMed ID: 28475554
    [Abstract] [Full Text] [Related]

  • 40. BREATHER (PENTA 16) short-cycle therapy (SCT) (5 days on/2 days off) in young people with chronic human immunodeficiency virus infection: an open, randomised, parallel-group Phase II/III trial.
    Butler K, Inshaw J, Ford D, Bernays S, Scott K, Kenny J, Klein N, Turkova A, Harper L, Nastouli E, Paparini S, Choudhury R, Rhodes T, Babiker A, Gibb D.
    Health Technol Assess; 2016 Jun 16; 20(49):1-108. PubMed ID: 27377073
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 58.